# A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors

> **NCT00528619** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 96 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Sunitinib, Pemetrexed, Cisplatin, Carboplatin

## Key facts

- **NCT ID:** NCT00528619
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2011-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00528619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00528619, "A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00528619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*